NICE Confirms English Funding For Three COVID-19 Drugs, But Rejects Four Others
There is good news for medicines from Pfizer, GSK and Roche, but MSD, Gilead and AstraZeneca have all appealed against NICE’s decision not to recommend their products for treating COVID-19.
You may also be interested in...
AstraZeneca Proclaims Promising Long-Acting COVID-19 Antibody
AstraZeneca vaccine chief Mark Esser is excited about the first in vitro data on AZD3152 which show that the antibody neutralizes all known variants, from Wuhan to Omicron XBB.1.5.
Cost Recovery Features In UK NICE’s Proposal For Rapidly Updating COVID-19 Treatment Recommendations
The health technology appraisal institute, NICE, is seeking feedback on a new surveillance and rapid update process for COVID-19 treatments.
Three COVID-19 Drugs Clear UK Funding Hurdle But Olumiant No Longer In The Running
NICE says it is the first health technology assessment body to look at the non-pandemic use of COVID-19 treatments. It is also planning to launch a consultation on a new process for updating its recommendations on such products with a view to making them available more quickly if new variants emerge.